WO2024090916A1 - Composition pharmaceutique pour traiter le cancer comprenant un anticorps anti-igsf1 - Google Patents

Composition pharmaceutique pour traiter le cancer comprenant un anticorps anti-igsf1 Download PDF

Info

Publication number
WO2024090916A1
WO2024090916A1 PCT/KR2023/016436 KR2023016436W WO2024090916A1 WO 2024090916 A1 WO2024090916 A1 WO 2024090916A1 KR 2023016436 W KR2023016436 W KR 2023016436W WO 2024090916 A1 WO2024090916 A1 WO 2024090916A1
Authority
WO
WIPO (PCT)
Prior art keywords
cancer
antibody
igsf1
biliary tract
cells
Prior art date
Application number
PCT/KR2023/016436
Other languages
English (en)
Korean (ko)
Inventor
이민기
손혜진
이미소
배승건
이원준
Original Assignee
웰마커바이오 주식회사
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 웰마커바이오 주식회사 filed Critical 웰마커바이오 주식회사
Publication of WO2024090916A1 publication Critical patent/WO2024090916A1/fr

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Definitions

  • the present invention relates to a pharmaceutical composition for preventing or treating cancer comprising an anti-IGSF1 antibody or fragment thereof as an active ingredient.
  • Cancer is one of the greatest diseases threatening human health. It is a disease that occurs when cells undergo a series of mutations, proliferate in an unlimited and uncontrolled manner, and become immortal. Causes of cancer include environmental or external factors such as chemicals, viruses, bacteria, and ionizing radiation, and internal factors such as congenital genetic mutations. For cancer discovered in the early stages, there are treatments such as surgery, radiation therapy, and chemotherapy, but their side effects are becoming a major problem, and for terminal cancer or metastatic cancer, life is terminal and ends without any special treatment.
  • epidermal growth factor receptor such as FOLFIRI (Folinic acid, Fluorouracil and Irinotecan), FOLFOX (Folinic acid, Fluorouracil and Oxaliplatin), Erbitux, Vectibix, etc.
  • FOLFIRI Fluorouracil and Irinotecan
  • FOLFOX Fluorouracil and Oxaliplatin
  • Erbitux Vectibix
  • Receptor-targeted anticancer antibody treatments and angiogenesis inhibitors such as Avastin or Zaltrap are mainly used as anticancer treatments.
  • the treatment response rate in patients who have received a prescription is very low at about 20%, or the recurrence rate within 3 years is high in patients who have shown treatment effects, and the drug is showing limited effectiveness, such as lack of response to the drug or resistance occurring after treatment. .
  • Biliary tract cancer has the characteristic that surgical resection is not effective due to its high recurrence rate and that it does not respond well to conventional chemotherapy or radiotherapy.
  • Biliary tract cancer is treated as a first-line treatment with Gemcitabine, Capecitabine, or 5-Fluorouracil (5-FU) as single agents, or with Oxaliplatin or Cisplatin. It is recommended to use it in combination with platinum compounds such as ), or in combination with gemcitabine and capecitabine.
  • multi-agent chemotherapy does not show lasting effects in patients with metastatic and/or recurrent biliary tract cancer, and in the case of advanced biliary tract cancer, the 5-year survival rate after diagnosis is less than 5%.
  • cisplatin a representative anticancer drug for the treatment of head and neck cancer, has excellent anticancer effects, but in the case of patients with cisplatin resistance or patients who develop resistance during the treatment process, problems to overcome resistance are needed. am.
  • the present inventors studied a method for effectively treating cancer and completed the present invention by confirming that tumor growth was inhibited by administration of an anti-IGSF1 antibody or fragment thereof.
  • one aspect of the present invention is to prevent or treat any one cancer selected from the group consisting of colon cancer, biliary tract cancer, and head and neck cancer, comprising an anti-IGSF1 antibody or fragment thereof as an active ingredient.
  • a pharmaceutical composition is provided.
  • Another aspect of the present invention provides a method for preventing or treating any one cancer selected from the group consisting of colon cancer, biliary tract cancer, and head and neck cancer, comprising administering an anti-IGSF1 antibody or fragment thereof to a subject.
  • Another aspect of the present invention provides an anti-IGSF1 antibody or fragment thereof for use in the prevention or treatment of any one cancer selected from the group consisting of colon cancer, biliary tract cancer, and head and neck cancer.
  • Another aspect of the present invention provides the use of an anti-IGSF1 antibody or fragment thereof for the manufacture of a medicament for preventing or treating any one cancer selected from the group consisting of colon cancer, biliary tract cancer, and head and neck cancer.
  • the anti-IGSF1 antibody according to the present invention When the anti-IGSF1 antibody according to the present invention was treated with colon cancer cells, biliary tract cancer cells, or head and neck cancer cells and immune cells, the secretion of Granzyme B and the cytokines IFN- ⁇ and TNF- ⁇ increased. . It was confirmed that the growth of colon cancer or biliary tract cancer was inhibited when the antibody was administered to a xenograft or allogeneic colon cancer or biliary tract cancer implanted mouse model. Therefore, the anti-IGSF1 antibody of the present invention can be usefully used in the treatment of colon cancer, biliary tract cancer, and head and neck cancer.
  • Figure 1 is a diagram showing the results of confirming the expression of IGSF1 in human colon cancer cell line HT29 cells through flow cytometry.
  • Figure 2 is a graph showing the results of confirming changes in the secretion amount of Granzyme B, IFN- ⁇ , and TNF- ⁇ by treatment with WM-A1-3389 antibody in a co-culture system of HT29 cells and human peripheral blood cells (PBMC).
  • PBMC peripheral blood cells
  • Figure 3 is a graph showing the results of measuring the degree of tumor growth by administration of WM-A1-3389 antibody in a mouse model implanted with the human colon cancer cell line HT29.
  • Figure 4 is a diagram showing the results of confirming the expression of IGSF1 in the mouse colon cancer cell line MC38 through immunofluorescence staining (top) and flow cytometry (bottom).
  • Figure 5 is a graph showing the results of measuring the degree of tumor growth by administration of WM-A1-3389 antibody in a mouse model implanted with the mouse colon cancer cell line MC38.
  • Figure 6 is a diagram showing the results of confirming the expression of IGSF1 in the mouse colon cancer cell line CT26 through immunofluorescence staining (top) and flow cytometry (bottom).
  • Figure 7 is a graph showing the results of measuring the degree of tumor growth by administration of WM-A1-3389 antibody in a mouse model implanted with the mouse colon cancer cell line CT26.
  • Figure 8 is a diagram showing the results of confirming the expression of IGSF1 in human biliary tract cancer cell line Choi-CK cells through flow cytometry.
  • Figure 9 is a graph showing the results of confirming changes in the secretion amount of Granzyme B, IFN- ⁇ , and TNF- ⁇ by treatment with WM-A1-3389 antibody in a co-culture system of Choi-CK cells and human peripheral blood cells (hPBMC).
  • Figure 10 is a graph showing the results of measuring the degree of tumor growth by administration of WM-A1-3389 antibody in a mouse model implanted with the human biliary tract cancer cell line Choi-CK.
  • Figure 11 is a diagram showing the results of confirming the expression of IGSF1 in the human head and neck cancer cell line FaDu cells through flow cytometry.
  • Figure 12 is a graph showing the results confirming changes in the secretion amounts of Granzyme B, IFN- ⁇ , and TNF- ⁇ by treatment with WM-A1-3389 antibody in the FaDu cell and human peripheral blood cell (hPBMC) co-culture system.
  • IGSF1 is a membrane protein encoded by the IGSF1 gene found on the X chromosome of humans and other mammalian species. Although the function of IGSF1 in normal cells is not well known, IGSF1 mutations are known to cause diseases such as IGSF1 deficiency syndrome or central hypothyroidism.
  • the IGSF1 may be included without limitation as long as it is mammalian IGSF1, but preferably refers to human IGSF1. Additionally, in the present invention, the IGSF1 protein includes, but is not limited to, both native and mutant IGSF1 proteins.
  • the native IGSF1 protein generally refers to a polypeptide containing the amino acid sequence of the native IGSF1 protein, and the amino acid sequence of the native IGSF1 protein generally refers to the amino acid sequence found in naturally occurring IGSF1.
  • Information about IGSF1 can be obtained from known databases such as GenBank of the National Institutes of Health, and may have, for example, an amino acid sequence (SEQ ID NO: 19) with Genbank accession number NP_001164433.1, but is not limited thereto.
  • antibody refers to an immunoglobulin molecule that reacts immunologically with a specific antigen, and refers to a protein molecule that specifically recognizes the antigen.
  • the antibodies include whole antibodies, monoclonal antibodies, polyclonal antibodies, single domain antibodies, single chain antibodies, multispecific antibodies, human antibodies, humanized antibodies, chimeric antibodies, intrabodies, scFvs, Fab fragments, F (ab') fragment, disulfide bond-linked Fv (sdFv), and epitope-binding fragments of any of the above.
  • anti-IGSF1 antibody refers to an antibody capable of specifically binding to IGSF1, and may be used interchangeably with “IGSF1-specific antibody” in the present invention.
  • anti-IGSF1 antibodies can specifically bind to the C terminus of IGSF1.
  • the form of the antibody may include both whole antibodies and antibody fragments thereof.
  • the heavy and light chains of immunoglobulins may each include a constant region and a variable region.
  • the light and heavy chain variable regions of immunoglobulins include three variable regions called complementarity determining regions (CDRs) and four framework regions (FRs).
  • CDRs complementarity determining regions
  • FRs framework regions
  • the CDR mainly functions to bind to the epitope of the antigen.
  • the CDRs of each chain are typically called CDR1, CDR2, and CDR3 sequentially, starting from the N terminus, and are identified by the chain on which the specific CDR is located.
  • the anti-IGSF1 antibody or fragment thereof of the present invention includes H-CDR1 containing the amino acid sequence of SEQ ID NO: 1, H-CDR2 containing the amino acid sequence of SEQ ID NO: 2, and H-CDR3 containing the amino acid sequence of SEQ ID NO: 3. It may include a heavy chain variable region (VH).
  • the anti-IGSF1 antibody or fragment thereof of the present invention includes L-CDR1 containing the amino acid sequence of SEQ ID NO: 4, L-CDR2 containing the amino acid sequence of SEQ ID NO: 5, and L- CDR2 containing the amino acid sequence of SEQ ID NO: 6. It may include a light chain variable region (VL) including CDR3.
  • the heavy chain variable region may include the amino acid sequence of SEQ ID NO: 7, and the light chain variable region may include the amino acid sequence of SEQ ID NO: 8.
  • the antibody may be referred to as WM-A1-3389.
  • the heavy chain variable region of the antibody consists of the amino acid sequence of SEQ ID NO: 7 and about 90% or more, about 91% or more, about 92% or more, about 93% or more, about 94% or more, about 95% or more, about 96% or more, about It may comprise or consist of an amino acid sequence having at least 97%, at least about 98%, at least about 99%, or 100% identity.
  • the light chain variable region of the antibody is about 90% or more, about 91% or more, about 92% or more, about 93% or more, about 94% or more, about 95% or more, and about 96% or more of the amino acid sequence of SEQ ID NO: 8. , may include or consist of an amino acid sequence having an identity of at least about 97%, at least about 98%, at least about 99%, or 100%.
  • Immunoglobulin heavy chain constant regions exhibit different amino acid compositions and sequences and therefore possess different types of antigenicity. Accordingly, immunoglobulins can be divided into five categories and referred to as immunoglobulin isotypes, namely IgM, IgD, IgG, IgA and IgE.
  • the corresponding heavy chains are ⁇ chain, ⁇ chain, ⁇ chain, ⁇ chain and ⁇ chain, respectively.
  • the same type of Ig can be classified into different subtypes. For example, IgG can be classified as IgG1, IgG2, IgG3, and IgG4.
  • Light chains can be classified as ⁇ or ⁇ chains depending on their different constant regions. Each of the five types of IgG can have either a ⁇ or ⁇ chain.
  • the anti-IGSF1 antibody or fragment thereof of the present invention may include a constant region derived from IgG, IgA, IgD, IgE, IgM, or a partial hybrid thereof.
  • hybrid means that sequences corresponding to immunoglobulin heavy chain constant regions of two or more different origins exist within the single-chain immunoglobulin heavy chain constant region.
  • a domain hybrid consisting of 1 to 4 domains selected from the group consisting of CH1, CH2, and CH3 of IgG, IgA, IgD, IgE, and IgM is possible.
  • the anti-IGSF1 antibody or fragment thereof of the present invention includes a light chain constant region (LC)
  • the light chain constant region may be derived from a ⁇ or ⁇ light chain.
  • antibody fragment refers to an scFv fragment, which is an Fv fragment that binds to IGSF1, as well as a Fab fragment, Fab' fragment, and F(ab') 2 fragment having antigen-binding activity, and is used in the present invention. Contains the CDR regions of the antibodies described in.
  • the Fv fragment is the smallest antibody fragment that contains the heavy and light chain variable regions, without constant regions, and retains all antigen-binding sites.
  • the pharmaceutical composition containing the anti-IGSF1 antibody or fragment thereof of the present invention as an active ingredient exhibits preventive or therapeutic efficacy against any one cancer selected from the group consisting of colon cancer, biliary tract cancer, and head and neck cancer.
  • the colon cancer, biliary tract cancer, and head and neck cancer may be cancers in which IGSF1 is overexpressed.
  • colon cancer used in the present invention refers to a malignant tumor composed of cancer cells that arise in the large intestine (cecum, appendix, colon, rectum, or anal canal). Pathologically, colon cancer is mostly adenocarcinoma, but it also includes lymphoma, sarcoma, squamous cell carcinoma, and metastatic lesions of other cancers. By site, it is largely divided into colon cancer and rectal cancer, with the highest incidence of cancer occurring in the lower colon, or rectum, at about 50%. The cause of colon cancer is still unclear, but genetic factors, dietary habits related to the consumption of high-fat and low-fiber foods, and inflammatory bowel disease are being considered. Colon cancer can occur at any age, but the incidence increases with age and occurs frequently in people in their 50s or 60s. The incidence ratio between men and women is somewhat higher for colon cancer in women and for rectal cancer in men.
  • biliary tract cancer used in this specification is also called cholangiocarcinoma and refers to cancer that occurs in the bile ducts.
  • the bile duct is a tube that transports bile produced in the liver to the duodenum. Cancers originating in the bile duct are divided into intrahepatic bile duct cancer (about 20% to about 25%), hilar bile duct cancer (about 50% to about 60%), and distal liver cancer, depending on the anatomical location. It can be classified into bile duct cancer (about 20% to about 25%). Adenocarcinoma arising from cholangiocytes accounts for the majority of cholangiocarcinomas.
  • cholangiocarcinoma The cause of cholangiocarcinoma is not yet clearly known, and it is caused by chronic inflammation in the bile duct cells lining the bile ducts, bile duct stones, sclerosing cholangitis, liver dystomatosis, inflammatory bowel disease, and bile duct cysts caused by congenital dilatation of the bile ducts. It is known to be related to etc.
  • head and neck cancer refers to malignant tumors that occur in the face, nose, throat, mouth, larynx, pharynx, salivary glands, and thyroid gland, excluding tumors that occur in the brain and eyes.
  • cancer that occurs in the oral cavity is called oral cancer
  • cancer that occurs in the larynx, the organ that produces sound is called laryngeal cancer
  • cancer that occurs in the pharynx is called pharyngeal cancer.
  • the pharyngeal cancer is divided into nasopharyngeal cancer, oropharyngeal cancer, and hypopharyngeal cancer depending on the location of occurrence.
  • head and neck cancer includes cervical esophageal cancer, salivary gland cancer, salivary gland cancer, malignant lymphoma, malignant melanoma, and various soft tissue cancers, and thyroid cancer is included in head and neck cancer in a comprehensive sense.
  • Smoking and drinking are known to be traditional causes of head and neck cancer
  • nasopharyngeal cancer is known to be closely related to viral infection (Epstein Barr virus).
  • gastric acid reflux disease, esophageal disease, radiation or ultraviolet rays, vitamin or iron deficiency, etc. are known to be factors that increase the incidence of head and neck cancer.
  • prevention refers to all actions that suppress or delay the onset of a disease by administering the pharmaceutical composition.
  • treatment refers to any action that improves or beneficially changes the symptoms of a disease by administering the pharmaceutical composition.
  • the anti-IGSF1 antibody or fragment thereof may be included in any amount (effective amount) depending on use, formulation, formulation purpose, etc., as long as it can exhibit anti-cancer activity.
  • “effective amount” refers to the amount of active ingredient that can induce an anticancer effect. Such effective amounts can be determined experimentally within the scope of the ordinary ability of those skilled in the art.
  • the pharmaceutical composition of the present invention contains the antibody as an active ingredient in an amount of about 0.1% to about 90% by weight, specifically about 0.5% by weight to about 75% by weight, and more specifically about 1% by weight to about 1% by weight, based on the total weight of the composition. It can be contained at 50% by weight.
  • “enhanced efficacy” e.g., improvement in efficacy
  • the term "efficacy” means survival over a period of time, such as 1 year, 5 years, or 10 years, or disease-free survival, which can be determined by one or more parameters. You can. Additionally, the parameter may include that the size of at least one tumor in the subject is suppressed.
  • the pharmaceutical composition of the present invention may contain a conventional, non-toxic pharmaceutically acceptable carrier that is formulated into a preparation according to a conventional method.
  • the pharmaceutically acceptable carrier may be any carrier that is a non-toxic material suitable for delivery to a patient. Distilled water, alcohol, fats, waxes and inert solids may be included as carriers. Pharmacologically acceptable adjuvants (buffers, dispersants) may also be included in the pharmacological composition.
  • the term “pharmaceutically acceptable carrier” refers to a carrier or diluent that does not irritate living organisms and does not inhibit the biological activity and properties of the administered compound.
  • Acceptable pharmaceutical carriers in compositions formulated as liquid solutions include those that are sterile and biocompatible, such as saline solution, sterile water, Ringer's solution, buffered saline solution, albumin injection solution, dextrose solution, maltodextrin solution, glycerol, ethanol, and One or more of these ingredients can be mixed and used, and other common additives such as sweeteners, solubilizers, wetting agents, emulsifiers, isotonic agents, absorbents, antioxidants, preservatives, lubricants, fillers, buffers, and bacteriostatic agents are added as needed. can do.
  • compositions of the present invention can be prepared in a variety of formulations for parenteral administration (e.g., intramuscular, intravenous, or subcutaneous injection).
  • parenteral administration e.g., intramuscular, intravenous, or subcutaneous injection.
  • the pharmaceutical composition of the present invention can be formulated in the form of injections, transdermal administration, nasal inhalation, and suppositories along with a suitable carrier according to methods known in the art.
  • injectable preparations include sterile aqueous solutions, non-aqueous solutions, suspensions, emulsions, lyophilized preparations, and suppositories.
  • Non-aqueous solvents and suspensions include propylene glycol, polyethylene glycol, vegetable oil such as olive oil, and injectable esters such as ethyl oleate.
  • injectables may contain conventional additives such as solubilizers, isotonic agents, suspending agents, emulsifiers, stabilizers, preservatives, etc.
  • the pharmaceutical composition of the present invention can be administered to a patient in a therapeutically effective amount or a pharmaceutically effective amount.
  • the term "administration” means introducing a predetermined substance into an individual by an appropriate method, and the composition may be administered through any general route as long as it can reach the target tissue. It may be administered intraperitoneally, intravenously, intramuscularly, subcutaneously, intradermally, locally, intranasally, or rectally, but is not limited thereto.
  • therapeutically effective amount refers to the amount of a compound or composition effective in preventing or treating the target disease, which is sufficient to treat the disease with a reasonable benefit/risk ratio applicable to medical treatment. This refers to an amount that does not cause side effects.
  • the level of the effective amount is determined by factors including the patient's health status, type and severity of the disease, drug activity, sensitivity to the drug, administration method, administration time, administration route and excretion rate, treatment period, combination or concurrent use of drugs, and It may be determined based on other factors well known in the medical field.
  • a therapeutically effective amount refers to an amount of drug effective in treating the disease.
  • the dosage of the composition of the present invention may vary depending on the patient's age, gender, and weight, and is generally administered from about 0.1 mg to about 1,000 mg per kg of body weight, or from about 5 mg to about 200 mg per kg of body weight every day or every other day. Alternatively, it can be administered at intervals of 2 to 3 weeks, or divided into 1 to 3 times a day. However, since it may increase or decrease depending on the route of administration, severity of disease, gender, weight, age, etc., the scope of the present invention is not limited thereto.
  • subject refers to an object to which the composition of the present invention can be applied (prescribed), including humans, rats, mice, guinea pigs, hamsters, rabbits, dogs, cats, chickens (including eggs), pigs, monkeys, It may be a mammal such as a goat. Preferably, it may be a human, but is not limited thereto.
  • the pharmaceutical composition of the present invention may be administered as an individual therapeutic agent or in combination with other therapeutic agents, may be administered sequentially or simultaneously with conventional therapeutic agents, and may be administered singly or multiple times.
  • the other therapeutic agent may additionally include any compound or natural extract whose safety has already been verified and which is known to have anticancer activity in order to increase or reinforce the anticancer activity.
  • Another aspect of the present invention is to treat any one cancer selected from the group consisting of colon cancer, biliary tract cancer, and head and neck cancer, comprising administering to an individual a pharmaceutical composition containing an anti-IGSF1 antibody or fragment thereof as an active ingredient.
  • a pharmaceutical composition containing an anti-IGSF1 antibody or fragment thereof as an active ingredient comprising administering to an individual a pharmaceutical composition containing an anti-IGSF1 antibody or fragment thereof as an active ingredient.
  • anti-IGSF1 antibody and fragment thereof, pharmaceutical composition, colorectal cancer, biliary tract cancer, head and neck cancer, administration, treatment and prevention are the same as described above.
  • the subject may be a mammal, preferably a human. Additionally, the individual may be a patient with the disease or an individual who is likely to suffer from the disease.
  • the administration route, dosage, and frequency of administration of the pharmaceutical composition may be administered to the subject in various methods and amounts depending on the patient's condition and the presence or absence of side effects, and the optimal administration method, dosage, and frequency of administration can be determined by a person skilled in the art. You can select by range. Additionally, the anti-IGSF1 antibody or fragment thereof may be administered in combination with other drugs or biochemically active substances known to have therapeutic effects on the disease, or may be formulated in the form of a combination preparation with other drugs.
  • Another aspect of the present invention is the prevention or treatment of any one cancer selected from the group consisting of colon cancer, biliary tract cancer, and head and neck cancer using a pharmaceutical composition containing the anti-IGSF1 antibody or fragment thereof of the present invention as an active ingredient.
  • a pharmaceutical composition containing the anti-IGSF1 antibody or fragment thereof of the present invention as an active ingredient Provides a purpose.
  • the anti-IGSF1 antibody and fragment thereof, pharmaceutical composition, colon cancer, biliary tract cancer, head and neck cancer, treatment and prevention are the same as described above.
  • Another aspect of the present invention provides an anti-IGSF1 antibody or fragment thereof for use in the prevention or treatment of any one cancer selected from the group consisting of colon cancer, biliary tract cancer, and head and neck cancer.
  • the anti-IGSF1 antibody and fragment thereof, pharmaceutical composition, colon cancer, biliary tract cancer, head and neck cancer, treatment and prevention are the same as described above.
  • Another aspect of the present invention provides the use of an anti-IGSF1 antibody or fragment thereof for the manufacture of a medicament for preventing or treating any one cancer selected from the group consisting of colon cancer, biliary tract cancer, and head and neck cancer.
  • the anti-IGSF1 antibody and fragment thereof, pharmaceutical composition, colon cancer, biliary tract cancer, head and neck cancer, prevention and treatment are the same as described above.
  • IGSF1 protein expression vector was created by fusing a polynucleotide encoding hig tag).
  • HEK293F cells were transfected with the prepared IGSF1 expression vector and then cultured for 6 days in medium supplemented with 1 mM valporic acid (valproate). Then, after primary purification of the IGSF1 extracellular domain using protein A agarose, secondary purification of the IGSF1 extracellular domain using Superdex 200 gel filtration chromatography, It was used for antibody selection.
  • bio-panning bio-panning, Y Biologics Co., Ltd.
  • bio-panning Y Biologics Co., Ltd.
  • human antibody library phage Y Biologics Co., Ltd.
  • the second and third rounds of biopanning were performed using the phage amplified in the first round of biopanning.
  • ELISA was performed to confirm the antigen specificity of the positive phage antibody pool obtained through each round of biopanning. In addition, it was confirmed that anti-IGSF1 antibody was enriched in the phage pool obtained through the third round.
  • the most optimized antibody was selected and named “WM-A1-3389”.
  • the CDR sequence of the WM-A1-3389 antibody is shown in Table 1 below.
  • a polynucleotide (SEQ ID NO: 23) encoding the heavy chain (SEQ ID NO: 21) was loaded into the N293F vector (Y Biologics Co., Ltd.) (hereinafter referred to as HC DNA).
  • a polynucleotide (SEQ ID NO: 24) encoding the light chain (SEQ ID NO: 22) was loaded into the N293F vector (Y Biologics Co., Ltd.) (hereinafter referred to as LC DNA).
  • LC DNA N293F vector
  • IGSF1 was confirmed in HT29 cells, a human colon cancer cell line.
  • the medium of HT29 cells was removed, washed once with PBS, and then treated with 2 ml of Accutase to separate the cells.
  • the separated cells were diluted in 8 ml of PBS (hereinafter referred to as FACS buffer) containing 2% (v/v) FBS and 0.05% (w/v) sodium azide, then centrifuged at 1,200 rpm for 1 minute to remove the supernatant. did.
  • the cell pellet was released with a vortex and resuspended with an appropriate amount of FACS buffer, and the number of cells was counted using trypan blue and distributed to each tube to reach 1 ⁇ 10 5 cells.
  • FACS buffer 200 ⁇ l was added to the remaining cell pellet, resuspended, and analyzed by FACS.
  • fluorescence value of Alexa 647 labeled in each cell was measured using BD LSRFortessa Flow cytometry (BD Bioscience), and the results were analyzed using FLowJo software.
  • Example 2.2 Confirmation of changes in cytokine secretion by co-culture of human colon cancer cell lines and peripheral blood cells
  • hPBMC human-derived peripheral blood cells
  • HT29 colon cancer cells and hPBMC were inoculated at a 1:1 ratio, and 1 ⁇ g/ml SEB (Sigma), 10 ⁇ g/ml IgG (Bio The cells were treated and cultured in a carbon dioxide incubator at 37°C for 24 hours. At this time, IgG was used as a negative control.
  • the supernatant of the co-cultured cells was collected in a 1.5 ml Eppendorf tube and the amount of cytokine secretion was measured through Cytometric bead array (CBA) assay.
  • CBA Cytometric bead array
  • the CBA assay used a BD Biosciences product and was performed according to the BD Biosciences protocol. Standard (standard sample) and co-cultured cell supernatant were added to each tube, capture beads were added, and reaction was performed at room temperature for 1 to 2 hours. After reaction, PE detection reagent was added and further reaction was performed at room temperature for 2 hours. Each tube was washed with washing buffer and measured using LSRFortessaTM Flow Cytometry equipment (BD Bioscience).
  • the secretion amount of cytokines IFN- ⁇ and TNF- ⁇ , including Granzyme B, in HT29 colon cancer cells expressing IGSF1 was statistically significantly lower in the group treated with the WM-A1-3389 antibody compared to the control group. It was confirmed that there was a significant increase.
  • Example 2.3 Confirmation of anticancer activity of WM-A1-3389 antibody in xenogeneic colon cancer cell line transplantation mouse model
  • the anticancer activity of the WM-A1-3389 antibody was confirmed in a colon cancer mouse model transplanted with a human colon cancer cell line.
  • mice 6-week-old female peripheral blood mononuclear cell humanized mice (Gem biosciences) were purchased and acclimatized for 1 week, and then HT29 cells, a human colon cancer cell line, were diluted in PBS and instilled on the right ventral side to a concentration of 5 ⁇ 10 6 cells/mice. It was injected subcutaneously (100 ⁇ l). Human IgG isotype was used as a negative control for the WM-A1-3389 antibody. When the tumor size reached an average of 140 mm 3 to 160 mm 3 , human IgG isotype (negative control) was administered intraperitoneally at a dose of 10 mg/kg or WM-A1-3389 antibody at a dose of 30 mg/kg. Administration was conducted once every three days for four weeks, and the tumor size and body weight of the mice were measured twice a week. On the 28th day of administration, the experimental animals were euthanized and the tumors were extracted and weighed.
  • HT29 cells a human colon cancer cell line
  • the WM-A1-3389 antibody administration group showed higher tumor growth inhibition efficacy than the negative control group.
  • TGI tumor growth inhibition
  • TGI tumor growth inhibition
  • Example 2.4 Confirmation of anticancer activity of WM-A1-3389 antibody in allogeneic colon cancer cell line transplantation mouse model
  • IGSF1 in MC38 cells was confirmed through immunofluorescence staining and flow cytometry. Immunofluorescence staining was performed as follows. Cells with the supernatant removed were fixed with 4% (v/v) formaldehyde (PFA, T&I) at room temperature for 15 minutes. The fixed cells were washed twice with PBS, blocking buffer was added to prevent non-specific binding, and reacted at room temperature for 1 hour. After the reaction, the primary IGSF1 antibody (sc-393786, Santa Cruz Biotechnology) was treated at a ratio of 1:100 and reacted at 4°C for more than 12 hours, protected from light.
  • PFA formaldehyde
  • the cells were washed twice with PBS, treated with anti-mouse IgG H&L (Alexa 488) (ab150113, Abcam) antibody as a secondary antibody at a ratio of 1:100, and incubated for 1 hour at room temperature, shielded from light.
  • the stained cells were washed twice with PBS and observed under a fluorescence microscope (Olympus). Flow cytometry was performed in the same manner as Example 2.1.
  • Example 2.4.2 Confirmation of anticancer activity of WM-A1-3389 antibody in mouse colon cancer cell line MC38 implanted mouse model
  • the anticancer activity of the WM-A1-3389 antibody was confirmed in a colon cancer mouse model (MC38 syngeneic mouse model) transplanted with MC38 cells, a mouse colon cancer cell line.
  • mice 5-week-old female C57BL/6N mice were purchased and acclimatized for 1 week.
  • Mouse colon cancer cells MC38 cells were diluted in PBS to prepare a concentration of 2.5 ⁇ 10 5 cells/mice, and MC38 cells were injected subcutaneously (100 ⁇ l) into the right ventral side of the mouse.
  • Mouse IgG isotype was used as a negative control for the WM-A1-3389 antibody.
  • mouse IgG isotype negative control
  • mice was administered intraperitoneally at doses of 10 mg/kg and WM-A1-3389 antibody at doses of 3, 10, and 30 mg/kg, respectively.
  • Administration was performed once every three days for two weeks, and the tumor size and body weight of the mice were measured twice a week. On the 14th day of administration, the experimental animals were euthanized and the tumors were extracted and weighed.
  • the WM-A1-3389 antibody administered group showed higher tumor growth inhibition efficacy than the negative control group, and a correlation was confirmed in which the tumor growth inhibition rate (TGI) increased in a dose-dependent manner.
  • TGI tumor growth inhibition rate
  • the WM-A1-3389 antibody dosage and tumor growth inhibition rate (TGI) are listed in Table 4 below.
  • WM-A1-3389 antibody administration group Dose(mg/kg) 3 10 30 TGI(%) 50.8 ⁇ 4.3 58.2 ⁇ 4.8 68.7 ⁇ 3.8
  • IGSF1 in CT26 cells, a mouse colon cancer cell line, was confirmed through immunofluorescence staining and flow cytometry. Immunofluorescence staining was performed in the same manner as in Example 2.4.1, and flow cytometry was performed in the same manner as in Example 2.1.
  • Example 2.4.4 Confirmation of anticancer activity of WM-A1-3389 antibody in mouse colon cancer cell line CT26 implanted mouse model
  • the anticancer activity of the WM-A1-3389 antibody was confirmed in a colon cancer mouse model (CT26 syngeneic mouse model) transplanted with CT26 cells, a mouse colon cancer cell line.
  • mice 5-week-old female C57BL/6N mice were purchased, acclimatized for 1 week, and mouse colon cancer CT26 cells were diluted in PBS and injected subcutaneously (100 ⁇ l) into the right ventral side to a concentration of 2.5 ⁇ 10 5 cells/mice. did.
  • Human IgG isotype was used as a negative control for the WM-A1-3389 antibody.
  • 10 mg/kg of mouse IgG isotype (negative control) and WM-A1-3389 antibody were administered intraperitoneally at doses of 3, 10, and 50 mg/kg, respectively.
  • Administration was performed once every three days for two weeks, and the tumor size and body weight of the mice were measured twice a week. On the 14th day of administration, the experimental animals were euthanized, the tumors were extracted, and their weight was measured.
  • the WM-A1-3389 antibody administered group showed higher tumor growth inhibition efficacy than the negative control group, and a correlation was confirmed in which the tumor growth inhibition rate (TGI) increased in a dose-dependent manner.
  • TGI tumor growth inhibition rate
  • the WM-A1-3389 antibody dosage and tumor growth inhibition rate (TGI) are listed in Table 5 below.
  • WM-A1-3389 antibody administration group Dose (mg/kg) 3 10 50 TGI (%) 44.9 ⁇ 3.8 57.0 ⁇ 3.5 66.0 ⁇ 3.5
  • the proportion of cells expressing IGSF1 in the Choi-CK cell line was found to be about 57.5%.
  • Example 3.2 Confirmation of changes in cytokine secretion by co-culture of human biliary tract cancer cell lines and peripheral blood cells
  • Example 3.3 Confirmation of anticancer activity of WM-A1-3389 antibody in xenograft biliary tract cancer cell line transplantation mouse model
  • the anticancer activity of the WM-A1-3389 antibody was confirmed in a biliary tract cancer mouse model transplanted with a human biliary tract cancer cell line.
  • mice 6-week-old female peripheral blood mononuclear cell humanized mice (Gem biosciences) were purchased and acclimatized for 1 week, and then Choi-CK cells, a human biliary tract cancer cell line, were diluted in PBS to a concentration of 5 ⁇ 10 6 cells/mice. It was injected subcutaneously (100 ⁇ l) on the dorsal side. Human IgG isotype was used as a negative control for the WM-A1-3389 antibody. When the tumor size reached an average of 80 mm 3 to 100 mm 3 , human IgG isotype (negative control) was administered intraperitoneally at a dose of 10 mg/kg or WM-A1-3389 antibody at a dose of 30 mg/kg. Administration was conducted once every three days for three weeks, and the tumor size and body weight of the mice were measured twice a week. On the 22nd day of administration, the experimental animals were euthanized and the tumors were extracted and weighed.
  • Choi-CK cells a human bil
  • the WM-A1-3389 antibody administration group showed higher tumor growth inhibition efficacy than the negative control group.
  • TGI tumor growth inhibition rate
  • TGI tumor growth inhibition
  • the proportion of cells expressing IGSF1 in the FaDu cell line was found to be about 37.7%.
  • Example 4.2 Confirmation of changes in cytokine secretion by co-culture of human head and neck cancer cell lines and peripheral blood cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La présente invention concerne une composition pharmaceutique pour le traitement du cancer du côlon, du cancer du tractus biliaire, ou du cancer de la tête et du cou, comprenant un anticorps anti-IGSF1 en tant que principe actif. Lorsque l'anticorps anti-IGSF1 selon la présente invention a été traité tout en co-cultivant des cellules du cancer du côlon, des cellules du cancer du tractus biliaire, ou des cellules du cancer de la tête et du cou avec des cellules immunitaires, la sécrétion de granzyme B, et des cytokines IFN-γ et TNF-α a été augmentée. Il a été confirmé que la croissance du cancer du côlon ou du cancer du tractus biliaire a été inhibée lorsque l'anticorps a été administré à un cancer du côlon xénogénique ou allogénique ou à un modèle de souris d'implantation de cancer du tractus biliaire. Par conséquent, l'anticorps anti-IGSF1 selon la présente invention peut être utile dans le traitement du cancer du côlon, du cancer du tractus biliaire et du cancer de la tête et du cou.
PCT/KR2023/016436 2022-10-24 2023-10-23 Composition pharmaceutique pour traiter le cancer comprenant un anticorps anti-igsf1 WO2024090916A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2022-0137536 2022-10-24
KR1020220137536A KR20240057508A (ko) 2022-10-24 2022-10-24 항-ｉｇｓｆ1 항체를 포함하는 암 치료용 약학 조성물

Publications (1)

Publication Number Publication Date
WO2024090916A1 true WO2024090916A1 (fr) 2024-05-02

Family

ID=90831271

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2023/016436 WO2024090916A1 (fr) 2022-10-24 2023-10-23 Composition pharmaceutique pour traiter le cancer comprenant un anticorps anti-igsf1

Country Status (2)

Country Link
KR (1) KR20240057508A (fr)
WO (1) WO2024090916A1 (fr)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110563845A (zh) * 2019-09-12 2019-12-13 滨州医学院 抗igsf9抗体、药物组合物及其应用
EP3176269B1 (fr) * 2014-07-29 2020-12-02 Wellmarker Bio Co., Ltd. Inhibiteurs de met et igsf1 pour le traitement du cancer
KR20210122185A (ko) * 2020-03-31 2021-10-08 웰마커바이오 주식회사 Igsf1에 대한 항체를 유효성분으로 포함하는 암 예방 또는 치료용 약학 조성물 및 이를 이용한 암 치료 방법
WO2023022271A1 (fr) * 2021-08-20 2023-02-23 웰마커바이오 주식회사 Anticorps anti-igsf1 et son utilisation

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3176269B1 (fr) * 2014-07-29 2020-12-02 Wellmarker Bio Co., Ltd. Inhibiteurs de met et igsf1 pour le traitement du cancer
CN110563845A (zh) * 2019-09-12 2019-12-13 滨州医学院 抗igsf9抗体、药物组合物及其应用
KR20210122185A (ko) * 2020-03-31 2021-10-08 웰마커바이오 주식회사 Igsf1에 대한 항체를 유효성분으로 포함하는 암 예방 또는 치료용 약학 조성물 및 이를 이용한 암 치료 방법
WO2023022271A1 (fr) * 2021-08-20 2023-02-23 웰마커바이오 주식회사 Anticorps anti-igsf1 et son utilisation

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
YAOYAO GUAN; YINGHAO WANG; ADHEESH BHANDARI; ERJIE XIA; OUCHEN WANG: "IGSF1: A novel oncogene regulates the thyroid cancer progression", CELL BIOCHEMISTRY AND FUNCTION., BUTTERWORTH, GUILDFORD., GB, vol. 37, no. 7, 25 July 2019 (2019-07-25), GB , pages 516 - 524, XP071523442, ISSN: 0263-6484, DOI: 10.1002/cbf.3426 *

Also Published As

Publication number Publication date
KR20240057508A (ko) 2024-05-03

Similar Documents

Publication Publication Date Title
JP4854912B2 (ja) 癌に対する抗体
US8734799B2 (en) Unconjugated anti-TfR antibodies and compositions thereof for the treatment of cancer
US20240117045A1 (en) Treatment of head and neck cancer
US11999788B2 (en) Treatment or prevention method of radiation damage by administration of IL-5 receptor alpha chain binding antibody
KR20180008571A (ko) 다발성 골수종(mm)의 치료
US20190270802A1 (en) Treating cancer with a combination of a pd-1 antagonist and an il-27 antagonist
KR20010101446A (ko) 항암 예방접종용 항체의 용도
WO2024090916A1 (fr) Composition pharmaceutique pour traiter le cancer comprenant un anticorps anti-igsf1
US20230416367A1 (en) Combination therapy of anti-pd-1 active agent, anti-tim-3 active agent, and anti-lag-3 active agent for treating cancer
EP4386000A1 (fr) Anticorps anti-cd25 humain recombinant et son utilisation
WO2023022271A1 (fr) Anticorps anti-igsf1 et son utilisation
WO2023211068A1 (fr) Composition pharmaceutique pour le traitement du cancer, comprenant un anticorps anti-igsf1 et un anticorps anti-pd-1
WO2020098785A1 (fr) Anticorps monoclonal anti-pd-l1 humain humanisé, son procédé de préparation et son utilisation
US20210087281A1 (en) Hgf-met agonist for use in the treatment of cancer and colorectal fibrosis
WO2022005068A1 (fr) Anticorps se liant de manière spécifique à lgals3bp et son utilisation
WO2023027507A1 (fr) Médicament à base d'anticorps pour la prévention ou le traitement de maladies auto-immunes
WO2023182657A1 (fr) Anticorps anti-fétuine-b et composition comprenant un anticorps correspondant en tant que principe actif pour la prévention, le traitement ou le soulagement de maladies musculaires
WO2023191470A1 (fr) Anticorps se liant de manière spécifique à la protéine api5
WO2022005171A1 (fr) Composition pour le traitement d'une maladie à coronavirus, comprenant un anticorps anti-ang2, et son utilisation
WO2024085726A1 (fr) Composition anticancéreuse comprenant un anticorps anti-vsig4
EP4349858A1 (fr) Récepteur antigénique chimérique se liant de manière spécifique à l'antigène cd300c ou à son récepteur
WO2024106939A1 (fr) Anticorps se liant de manière spécifique à b7-h3
WO2022131687A2 (fr) Anticorps anti-hvem ainsi que composition et procédé associés à celui-ci
TWI665215B (zh) 具有抑制致病原的免疫抑制功能的單株抗體，其抗原結合片段，以及產生該等抗體的融合瘤
Michieli HGF-MET AGONIST FOR USE IN THE TREATMENT OF CANCER AND COLORECTAL FIBROSIS

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23883022

Country of ref document: EP

Kind code of ref document: A1